0001209191-23-000948.txt : 20230104 0001209191-23-000948.hdr.sgml : 20230104 20230104163034 ACCESSION NUMBER: 0001209191-23-000948 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230103 FILED AS OF DATE: 20230104 DATE AS OF CHANGE: 20230104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Janku Filip CENTRAL INDEX KEY: 0001862930 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40522 FILM NUMBER: 23506934 MAIL ADDRESS: STREET 1: MONTE ROSA THERAPEUTICS, INC. STREET 2: 40 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc. CENTRAL INDEX KEY: 0001826457 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-949-2643 MAIL ADDRESS: STREET 1: 645 SUMMER STREET STREET 2: SUITE 102 CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-03 0 0001826457 Monte Rosa Therapeutics, Inc. GLUE 0001862930 Janku Filip MONTE ROSA THERAPEUTICS, INC. 645 SUMMER STREET, SUITE 102 BOSTON MA 02210 0 1 0 0 Chief Medical Officer Stock Option (Right to Buy) 7.78 2023-01-03 4 A 0 135000 0.00 A 2033-01-02 Common Stock 135000 135000 D 25% of this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. /s/ Ajim Tamboli, Attorney-in-Fact 2023-01-04